Close

Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

EYLEA HD® Phase 3 Trial Yields Promising Results

Regeneron Pharmaceuticals, Inc. announced promising results from the Phase...

Pfizer’s BRAFTOVI Improves Survival in Phase 3 Trial

Pfizer has announced groundbreaking results from the Phase 3...

FlyPharma 2025 Amsterdam officially announced as contracts are signed with host sponsors

FlyPharma, the leading platform for the pharmaceutical logistics and...

Neopac Becomes First European Tube Manufacturer to Achieve RecyClass EN 15343 Certification

Oberdiessbach, Switzerland – Neopac, a global provider of high-quality...

Mylan Inc.today announced that its UK and Italy-based subsidiaries have launched Ibandronic Acid Film Coated Tablets POM, 150 mg. This product is the generic version of Roche’s Bonviva® Tablets, a treatment for osteoporosis.

Mylan CEO Heather Breschsaid: “We are very proud to launch generic Ibandronic Acid on day one in both the UK and in Italy, as we continue to deliver on our commitment of providing high quality and affordable medicines to patients around the world.”

Mylan EMEA President Didier Barretsaid: “We are excited to be adding generic Ibandronic Acid to our strong portfolio of more than 350 products in the UK and 340 in Italy. Mylan was the first company to launch a generic Ibandronic Acid formulation in the UK. These launches follow our successful launch of this product in Spain last November.”

Ibandronic Acid Film Coated Tablets POM had sales of approximately 8.5 million euros (7.5 million Pounds Sterling) in the UK and sales of approximately 27 million euros in Italy for the 12 months ending March 2012, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what’s right, not what’s easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications.

In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don’t take our word for it. See for yourself. See inside. mylan.com

 

 

 

Latest stories